The Valley Desk

Clinical trial reportClinical pharmacology and therapeuticsPublished

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Clinical pharmacology and therapeutics
Published
Subject terms
Humans; Multiple Myeloma; Antibodies, Bispecific; Dose-Response Relationship, Drug; Half-Life; Adult; Aged; Middle Aged; Female; Male; Antineoplastic Agents, Immunological
PubMed ID
40704375
PubMed Central ID
PMC12439005
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal